Navigation Links
Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
Date:5/31/2013

(PRWEB) May 31, 2013

Merck’s diabetes drug Januvia can potentially cause pancreatic cancer, according to the research of Dr. Peter C. Butler reported in the New York Times.* The Rottenstein Law Group, which accepts clients in Januvia lawsuits, maintains a site at http://www.januvialawsuits.us that features information about the drug’s alleged side effects and eligibility for filing a lawsuit.

Butler, chairman of endocrinology at the University of California, Los Angeles, has been researching Januvia since 2008, when Merck asked him to determine if the drug could stave off disease in rats, according to the Times. What Butler found is changes in the pancreases of rats that could lead to cancer. His findings are having an impact on not only Januvia, but also sales of other type 2 diabetes drugs such as Byetta and Victoza, that are also linked to pancreatic cancer. His findings have led the U.S. Food and Drug Administration and its European counterpart to consider further investigation.

“If Dr. Butler’s findings are true, then Merck should be held accountable for the alleged Januvia side effects,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “Accountability in this case means that those who believed their medication has harmed them should have the opportunity to be compensated for their alleged harms.”

At its Januvia Lawsuits Center, the Rottenstein Law Group LLP features information on all the serious side effects of Januvia, news on the drug and information about how to file a Januvia lawsuit.

*nytimes.com/2013/05/31/business/a-doctor-raises-questions-about-a-diabetes-drug.html?pagewanted=all

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at injurylawyernewswire.com. Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

                            ###

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/pancreatic-cancer/prweb10787304.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Announces Addition of Januvia Cancer Resource Center
2. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
3. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
4. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
5. LawyersandSettlements.com Issues Report on Prostate Health Claim Lawsuits and Propecia Side Effect Litigation
6. The Law Office of Wolf & Pravato, The Alters Firm and Morelli Ratner File Class Action Lawsuit Against Global Spray Foam Manufacturer
7. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
8. New Lawsuit Alleges Teen Molestation by Ex-Deputy
9. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
10. New Lawsuit on Propecia: Severe Adverse Events
11. New Lawsuit on Accutane Crohn’s Disease: Severe Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first prospective ACL ... Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain ... decline over time. The study, presented today at the American Orthopaedic Society ...
(Date:7/20/2017)... ... , ... ChenMed , a leading provider of value-based care for seniors, ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine ... Ambulatory Services for the UVA Health System, brings 30 years of highly relevant experience ...
(Date:7/20/2017)... ... , ... For individuals with extended hospital stays or who are residents of ... are specially designed to accommodate patients with a wide range of ailments or special ... Ind., has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced ... Proceeds will be used to complete regulatory submissions and fund final engineering and ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... -- The Institute for In Vitro Sciences (IIVS), a ... a VITROCELL® inhalation exposure system thanks to a generous ... which is designed to replace animals in inhalation testing, ... airborne test materials in an environment that mimics the ... testing combustible tobacco products, as well as next generation ...
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... pharmaceutical company focused on the development of oral drug delivery ... Israel Securities Authority to dual-list its common stock on the ... trading on the TASE on July 12, 2017 under the ... Company, it is expected that Oramed will be included in ...
Breaking Medicine Technology: